Janux Therapeutics (JANX) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Janux Therapeutics (JANX) stock.

Latest Upgrades and Downgrades for Janux Therapeutics Stock

Date	Firm	Analyst	Action	Rating Change	Price Target
—	Wolfe Research	Kalpit Patel	Downgrade	Outperform→Peer Perform	—
—	Truist Securities	Supawat Thongthip	PT Raise	Buy	$26→$27
—	Wedbush	Robert Driscoll	PT Raise	Outperform	$36→$40
—	Barclays	Etzer Darout	PT Raise	Underweight	$14→$15
—	Wolfe Research	Kalpit Patel	Upgrade	Peer Perform→Outperform	$23
—	Guggenheim	Brad Canino	PT Cut	Buy	$58→$55
—	Truist Securities	Supawat Thongthip	Assumes	Buy	$80→$26
—	Piper Sandler	Kelsey Goodwin	PT Cut	Overweight	$30→$26
—	Wedbush	Robert Driscoll	PT Cut	Outperform	$45→$36
—	Guggenheim	Brad Canino	PT Cut	Buy	$68→$58
—	Jones Trading	Boris Peaker	PT Cut	Buy	$50→$28
—	Barclays	Etzer Darout	Downgrade	Overweight→Underweight	$29→$14
—	UBS	David Dai	Downgrade	Buy→Neutral	$57→$15
—	Cantor Fitzgerald	Josh Schimmer	PT Cut	Overweight	$150→$100
—	Guggenheim	Brad Canino	PT Cut	Buy	$72→$68
—	Clear Street	Kaveri Pohlman	Downgrade	Buy→Hold	$32→$12
—	Piper Sandler	Kelsey Goodwin	PT Cut	Overweight	$42→$30
—	Barclays	Etzer Darout	PT Cut	Overweight	$48→$29
—	Stifel	Bradley Canino	PT Cut	Buy	$46→$38
—	Clear Street	Kaveri Pohlman	PT Cut	Buy	$80→$32

Analyst Ratings News

PRO
Wolfe Research Downgrades Janux Therapeutics to Peer Perform

Wolfe Research analyst Kalpit Patel downgrades Janux Therapeutics (NASDAQ:JANX) from Outperform to Peer Perform.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Janux Therapeutics, Raises Price Target to $27

Truist Securities analyst Supawat Thongthip maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and raises the price target from $26 to $27.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Janux Therapeutics, Raises Price Target to $40

Wedbush analyst Robert Driscoll maintains Janux Therapeutics (NASDAQ:JANX) with a Outperform and raises the price target from $36 to $40.

Benzinga Newsdesk

PRO
Barclays Maintains Underweight on Janux Therapeutics, Raises Price Target to $15

Barclays analyst Etzer Darout maintains Janux Therapeutics (NASDAQ:JANX) with a Underweight and raises the price target from $14 to $15.

Benzinga Newsdesk

This Darden Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday

Top Wall Street analysts changed their outlook on top names. See analyst ratings page for full list. DRI, JANX, and more mentioned.

Avi Kapoor

PRO
Wolfe Research Upgrades Janux Therapeutics to Outperform, Announces $23 Price Target

Wolfe Research analyst Kalpit Patel upgrades Janux Therapeutics (NASDAQ:JANX) from Peer Perform to Outperform and announces $23 price target.

Benzinga Newsdesk

Janux Therapeutics Inc

Janux Therapeutics (JANX) Stock Price Target 2026

Latest Upgrades and Downgrades for Janux Therapeutics Stock

Janux Therapeutics (JANX) Stock Price Target 2026

Latest Upgrades and Downgrades for Janux Therapeutics Stock

Analyst Ratings News

PRO
Wolfe Research Downgrades Janux Therapeutics to Peer Perform

PRO
Truist Securities Maintains Buy on Janux Therapeutics, Raises Price Target to $27

PRO
Wedbush Maintains Outperform on Janux Therapeutics, Raises Price Target to $40

PRO
Barclays Maintains Underweight on Janux Therapeutics, Raises Price Target to $15

This Darden Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday

PRO
Wolfe Research Upgrades Janux Therapeutics to Outperform, Announces $23 Price Target

People Also Watch

People Also Watch

Analyst Ratings News

PRO
Wolfe Research Downgrades Janux Therapeutics to Peer Perform

PRO
Truist Securities Maintains Buy on Janux Therapeutics, Raises Price Target to $27

PRO
Wedbush Maintains Outperform on Janux Therapeutics, Raises Price Target to $40

PRO
Barclays Maintains Underweight on Janux Therapeutics, Raises Price Target to $15

This Darden Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday

PRO
Wolfe Research Upgrades Janux Therapeutics to Outperform, Announces $23 Price Target

Janux Therapeutics Inc

Janux Therapeutics (JANX) Stock Price Target 2026

Latest Upgrades and Downgrades for Janux Therapeutics Stock

Janux Therapeutics (JANX) Stock Price Target 2026

Latest Upgrades and Downgrades for Janux Therapeutics Stock

Analyst Ratings News

PROWolfe Research Downgrades Janux Therapeutics to Peer Perform

PROTruist Securities Maintains Buy on Janux Therapeutics, Raises Price Target to $27

PROWedbush Maintains Outperform on Janux Therapeutics, Raises Price Target to $40

PROBarclays Maintains Underweight on Janux Therapeutics, Raises Price Target to $15

This Darden Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday

PROWolfe Research Upgrades Janux Therapeutics to Outperform, Announces $23 Price Target

People Also Watch

People Also Watch

Analyst Ratings News

PROWolfe Research Downgrades Janux Therapeutics to Peer Perform

PROTruist Securities Maintains Buy on Janux Therapeutics, Raises Price Target to $27

PROWedbush Maintains Outperform on Janux Therapeutics, Raises Price Target to $40

PROBarclays Maintains Underweight on Janux Therapeutics, Raises Price Target to $15

This Darden Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday

PROWolfe Research Upgrades Janux Therapeutics to Outperform, Announces $23 Price Target

PRO
Wolfe Research Downgrades Janux Therapeutics to Peer Perform

PRO
Truist Securities Maintains Buy on Janux Therapeutics, Raises Price Target to $27

PRO
Wedbush Maintains Outperform on Janux Therapeutics, Raises Price Target to $40

PRO
Barclays Maintains Underweight on Janux Therapeutics, Raises Price Target to $15

PRO
Wolfe Research Upgrades Janux Therapeutics to Outperform, Announces $23 Price Target

PRO
Wolfe Research Downgrades Janux Therapeutics to Peer Perform

PRO
Truist Securities Maintains Buy on Janux Therapeutics, Raises Price Target to $27

PRO
Wedbush Maintains Outperform on Janux Therapeutics, Raises Price Target to $40

PRO
Barclays Maintains Underweight on Janux Therapeutics, Raises Price Target to $15

PRO
Wolfe Research Upgrades Janux Therapeutics to Outperform, Announces $23 Price Target